{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:57:01Z","timestamp":1772067421954,"version":"3.50.1"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T00:00:00Z","timestamp":1682035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:p>Post-traumatic stress disorder is a debilitating chronic illness that affects 6 out of 100 adults after a severe trauma. The alpha-adrenergic antagonist prazosin, which is prescribed off-label for flashbacks and nightmares due to trauma, is often continued indefinitely due to reports of symptoms returning upon discontinuation. There is no standard guidance for a trial of discontinuation of prazosin due to intolerance or side effects. In this case series, three patients are started on prazosin leading to remission of trauma-related symptoms, and symptoms continue to remit after treatment for an average of about 2 years followed by discontinuation of the medication. There are many similarities in these case reports which serve to provide guidance as to when a trial of prazosin discontinuation may be warranted.<\/jats:p>","DOI":"10.3389\/fpsyt.2023.1172754","type":"journal-article","created":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T04:26:17Z","timestamp":1682051177000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Case series: Continued remission of PTSD symptoms after discontinuation of prazosin"],"prefix":"10.3389","volume":"14","author":[{"given":"Christie","family":"Richardson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Yuh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Forsberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,21]]},"reference":[{"key":"ref1","volume-title":"Diagnostic and statistical manual of mental disorders","year":"2022"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1017\/S1092852920001121","article-title":"Prazosin for treatment of post-traumatic stress disorder: a systematic review and meta-analysis","volume":"26","author":"Reist","year":"2021","journal-title":"CNS Spectr"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/s0022-3956(02)00025-0","article-title":"Effects of comorbid diagnoses on sleep disturbance in PTSD","volume":"36","author":"Leskin","year":"2002","journal-title":"J Psychiatr Res"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.genhosppsych.2015.10.007","article-title":"Prazosin for treating sleep disturbances in adults with posttraumatic stress disorder: a systematic review and meta-analysis of randomized controlled trials","volume":"39","author":"Khachatryan","year":"2016","journal-title":"Gen Hosp Psychiatry"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1056\/nejmoa1507598","article-title":"Trial of Prazosin for post-traumatic stress disorder in military veterans","volume":"378","author":"Raskind","year":"2018","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.mayocp.2012.05.015","article-title":"Treatment of nightmares with prazosin: a systematic review","volume":"87","author":"Kung","year":"2012","journal-title":"Mayo Clin Proc"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1176\/appi.focus.16408","article-title":"Clinician summary","volume":"16","year":"2018","journal-title":"Focus"},{"key":"ref8","year":"2014"},{"key":"ref9","year":"2017"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"373","DOI":"10.9740\/mhc.2019.11.373","article-title":"Treatment of posttraumatic stress disorder: focus on pharmacotherapy","volume":"9","author":"Ehret","year":"2019","journal-title":"Mental Health Clinic"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"4175","DOI":"10.3390\/jcm10184175","article-title":"Treatment guidelines for PTSD: a systematic review","volume":"10","author":"Martin","year":"2021","journal-title":"J Clin Med"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1177\/2045125313500982","article-title":"High-dose prazosin for the treatment of post-traumatic stress disorder","volume":"4","author":"Koola","year":"2014","journal-title":"Therapeut Adv Psychopharmacol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"803220","DOI":"10.3389\/fpsyt.2022.803220","article-title":"Case report: Prazosin augmentation for treating comorbid treatment-resistant depression and chronic post-traumatic stress disorder","volume":"13","author":"Guo","year":"2022","journal-title":"Front Psych"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1176\/foc.7.2.foc204","article-title":"Guideline watch (march 2009): practice guideline for the treatment of patients with acute stress disorder and posttraumatic stress disorder","volume":"7","author":"Benedek","year":"2009","journal-title":"Focus"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.4088\/pcc.16r01943","article-title":"Efficacy of Prazosin in posttraumatic stress disorder","volume":"18","author":"Singh","year":"2016","journal-title":"Prim Care Companion CNS Disord"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"258","DOI":"10.3389\/fnbeh.2018.00258","article-title":"Treating PTSD: a review of evidence-based psychotherapy interventions","volume":"12","author":"Watkins","year":"2018","journal-title":"Front Behav Neurosci"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/s0304-3940(00)01674-8","article-title":"Brain function in a patient with torture related post-traumatic stress disorder before and after fluoxetine treatment: a positron emission tomography provocation study","volume":"297","author":"Fernandez","year":"2001","journal-title":"Neurosci Lett"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1159\/000126223","article-title":"Participation of \u03b1-1-adrenergic receptors in the secretion of hypothalamic Corticotropin-releasing hormone during stress","volume":"56","author":"Kiss","year":"1992","journal-title":"Neuroendocrinology"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1176\/appi.ajp.160.2.371","article-title":"Reduction of nightmares and other PTSD symptoms in combat veterans by Prazosin: a placebo-controlled study","volume":"160","author":"Raskind","year":"2003","journal-title":"Am J Psychiatr"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"PCC.11r01222","DOI":"10.4088\/pcc.11r01222","article-title":"Prazosin for the treatment of nightmares related to posttraumatic stress disorder","volume":"14","author":"Hudson","year":"2012","journal-title":"Prim Care Companion CNS Disord"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"219","DOI":"10.9758\/cpn.2020.18.2.219","article-title":"The neurochemical effects of Prazosin treatment on fear circuitry in a rat traumatic stress model","volume":"18","author":"Ketenci","year":"2020","journal-title":"Clin Psychopharmacol Neurosci"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2023.1172754\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T04:26:20Z","timestamp":1682051180000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2023.1172754\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,21]]},"references-count":21,"alternative-id":["10.3389\/fpsyt.2023.1172754"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2023.1172754","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,21]]},"article-number":"1172754"}}